JPH1036256A - Anti-osteoporosis composition - Google Patents

Anti-osteoporosis composition

Info

Publication number
JPH1036256A
JPH1036256A JP8193124A JP19312496A JPH1036256A JP H1036256 A JPH1036256 A JP H1036256A JP 8193124 A JP8193124 A JP 8193124A JP 19312496 A JP19312496 A JP 19312496A JP H1036256 A JPH1036256 A JP H1036256A
Authority
JP
Japan
Prior art keywords
vitamin
zinc
osteoporosis
composition
bone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP8193124A
Other languages
Japanese (ja)
Other versions
JP3459932B2 (en
Inventor
Masayoshi Yamaguchi
正義 山口
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16302669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPH1036256(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to JP19312496A priority Critical patent/JP3459932B2/en
Publication of JPH1036256A publication Critical patent/JPH1036256A/en
Application granted granted Critical
Publication of JP3459932B2 publication Critical patent/JP3459932B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

PROBLEM TO BE SOLVED: To obtain an anti-osteoporosis composition safe in continuous intake, comprising vitamin K2 and zinc as active ingredients. SOLUTION: This composition comprises vitamin K2 and zinc. Vitamin K2 derived from Bacillus natto or Bacillus subtilis is preferable as the vitamin K2 and zinc derived from a food such as dried yeast or bovine bonemeal is used as zinc. The contents of the vitamin K2 and zinc are >=30mg in 1kg solid content, respectively and most preferably >=50mg. By possessing both the vitamin K2 and zinc, a higher bone action is promoted, to adverse effect is found, the composition is effective even with a small intake amount of the vitamin K2 and a nutrient component can also be enhanced.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】本発明は、有効成分としてビ
タミンK2 および亜鉛を共に含む、抗骨粗鬆症組成物に
関する。
[0001] The present invention relates to an anti-osteoporosis composition containing both vitamin K 2 and zinc as active ingredients.

【0002】[0002]

【従来の技術】骨粗鬆症は、骨量が減少することによっ
て起こる、骨がもろくなる病態である。骨粗鬆症になる
と、骨折したり、激しい痛みなどを伴うだけでなく、特
に老人の寝たきりの原因ともなるため、高齢化社会に於
ける生活の質の向上という観点からも、有効な治療方法
が求められている。
2. Description of the Related Art Osteoporosis is a condition in which bone becomes brittle due to a decrease in bone mass. Osteoporosis not only causes fractures and severe pain, but also causes bedridden especially for elderly people.Therefore, effective treatment methods are required from the viewpoint of improving the quality of life in an aging society. ing.

【0003】骨粗鬆症の治療薬としては活性型ビタミン
D3や女性ホルモン(エストロゲン)、カルシトニン、
イプリフラボンが臨床に用いられ、最近になって、ビタ
ミンK2 に代表されるポリイソプレノイド誘導体の破骨
細胞形成抑制作用に基づく抗骨粗鬆症剤(特開平7−2
15849号公報)も開発されている。
[0003] Therapeutic agents for osteoporosis include active vitamin D3, female hormones (estrogens), calcitonin,
Ipriflavone is used clinically, and recently, an anti-osteoporosis agent based on the osteoclast formation inhibitory action of a polyisoprenoid derivative represented by vitamin K 2 (Japanese Patent Laid-Open No. 7-2)
15849) has also been developed.

【0004】一方、最近では、骨粗鬆症は発症してから
治療するのは困難であることから、予防に努めることが
重要であり、若年期から骨量を増やすことが不可欠で、
日常的に骨形成に必要な栄養成分や、骨形成を促進する
食品を積極的に摂取するようにしなければならないこと
が深く認識されるようになった。骨を強化する食品とし
ては、現在、主にカルシウムやマグネシウム、ビタミン
Dが利用されている。また、カルシウムの腸管からの吸
収を促進するカゼインホスホペプチドなども利用されて
いる。更には、側鎖長の違いによりメナキノン(MK)
−1〜14として知られている食品のビタミンK2 を利
用することも考えられている。
On the other hand, recently, it is difficult to treat osteoporosis after it has developed, so it is important to work on prevention, and it is essential to increase bone mass from a young age.
It has been deeply recognized that it is necessary to actively take nutritional components necessary for bone formation and foods that promote bone formation on a daily basis. Currently, calcium, magnesium, and vitamin D are mainly used as foods for strengthening bones. Casein phosphopeptides that promote the absorption of calcium from the intestinal tract have also been used. Furthermore, depending on the side chain length, menaquinone (MK)
It is also believed that the use of vitamin K 2 of the food, which is known as -1~14.

【0005】[0005]

【発明が解決しようとする課題】ところが、骨粗鬆症の
治療薬として使用されている活性型ビタミンD3 、女性
ホルモン(エストロゲン)、カルシトニンは副作用や過
剰症があることが判り、問題となっている。最近になっ
て、安全性の高い骨粗鬆症治療薬としてビタミンK2
利用されるようになったが、治療に使うビタミンK2
は1日に45mgと多くの量を摂取しなければならず、
この場合軽微ながら、ときに腹痛、悪心、嘔吐、発疹、
頭痛などの副作用があらわれることがある。また、イプ
リフラボンは長期間に渡って使用した場合の有効性、安
全性が不明確である。このように、種々の骨粗鬆症治療
薬が開発されているにもかかわらず、長期間にわたって
投薬が行われるため副作用等による患者の負担が大き
く、必ずしも満足の行く治療効果が発揮されていない。
一方、カルシウム等の食品によって骨組成を補強する方
法も、骨量増加効果あるいは骨強度を高める効果は充分
なものとはいえない。
However, it has been found that active vitamin D 3 , a female hormone (estrogen) and calcitonin, which are used as a therapeutic agent for osteoporosis, have side effects and excessive symptoms, which is a problem. Recently, vitamin K 2 has been used as a safe drug for osteoporosis, but the amount of vitamin K 2 used for treatment must be as high as 45 mg a day,
In this case, minor, sometimes abdominal pain, nausea, vomiting, rash,
Side effects such as headaches may occur. In addition, the efficacy and safety of ipriflavone when used for a long period of time are unclear. As described above, despite the development of various therapeutic agents for osteoporosis, medication is performed for a long period of time, so that the burden on patients due to side effects and the like is large, and satisfactory therapeutic effects are not necessarily exerted.
On the other hand, the method of reinforcing the bone composition with foods such as calcium does not have a sufficient effect of increasing bone mass or enhancing bone strength.

【0006】また、ビタミンK2 についてもビタミンK
2 を1ppm 以上含む食品は存外少なく、身近な食品では
わずかに納豆(ビタミンK2 濃度、数〜十数ppm )にそ
の例を見出すのみである。その納豆によっても骨粗鬆症
治療に有効なビタミンK2 を摂取しようとした場合、納
豆を一日に数百g以上食べなければならず、嗜好上問題
がある。そこで、ビタミンK2 を強化した食品の開発が
試みられている。しかし、治療薬のように1日45mg
摂取させると、上述したように腹痛、発疹などの副作用
が現れることがあるため、これより少ない量しか使用す
ることはできないが、量を減らすと効果が減弱してしま
う。
[0006] In addition, vitamin K 2
2 food Zongai less including more than 1ppm a slightly natto in familiar foods (vitamin K 2 concentration, several to several tens of ppm) only finds its examples. If you try to ingest a valid vitamin K 2 in the treatment of osteoporosis by the natto, you must eat several hundred g or more a day natto, there is a preference on the problem. Therefore, attempts have been made to the development of food products with enhanced vitamin K 2. However, like a remedy 45mg a day
When ingested, side effects such as abdominal pain and rash may appear as described above, so that only a smaller amount can be used, but if the amount is reduced, the effect is reduced.

【0007】栄養指導以外に骨に荷重をかけて、骨形成
を促進させるために運動が推奨されているが、現実に
は、高齢になると体力の低下や気力の低下により運動不
足になりやすい傾向がみられる。また、当然ながら、運
動だけでは骨量、骨強度を十分に維持、増加させること
はできない。近年、骨組織中に亜鉛が多く含まれること
から、亜鉛の骨形成との関わりが研究され、亜鉛の骨形
成作用が確認されている。亜鉛は食品に広く含まれる
が、日本人の平均摂取量は6〜12mgであり、推奨摂
取量(成人15mg、四訂食品成分表1996、女子栄
養大学出版部)に対して不足気味である。従って、通常
の食事による亜鉛単独の骨作用は望むべくもない。ま
た、動物性食品や微生物を含む食品にはビタミンK2
亜鉛もともにごく微量含まれることが多いが、食品中に
含まれる量ではこれら2成分の骨に対する効果は大変弱
いものである。このように、骨粗鬆症の予防、あるいは
治療効果が優れた安全な機能性食品の開発が望まれてい
るにもかかわらず、現状では有効性と安全性をともに解
決した製品が開発されていない。
[0007] Exercise is recommended to promote bone formation by applying a load to bones in addition to nutritional guidance. However, in practice, older people tend to have a lack of exercise due to a decrease in physical strength and energy. Is seen. Naturally, exercise alone cannot sufficiently maintain and increase bone mass and bone strength. In recent years, since zinc is contained in a large amount in bone tissue, the relationship between zinc and bone formation has been studied, and the bone formation effect of zinc has been confirmed. Although zinc is widely contained in foods, the average intake for Japanese is 6 to 12 mg, which is insufficient for the recommended intake (15 mg for adults, four revised food composition table 1996, Women's Nutrition University Press). Thus, the bone effects of zinc alone with a normal diet are not desirable. In addition, animal foods and foods containing microorganisms often contain very small amounts of both vitamin K 2 and zinc, but the effects of these two components on bone are very weak at the amounts contained in the foods. As described above, although there is a demand for the development of a safe functional food having an excellent effect of preventing or treating osteoporosis, a product which has solved both the efficacy and the safety has not been developed at present.

【0008】[0008]

【課題を解決するための手段】本発明の目的は、上記課
題を解決しうる有効な抗骨粗鬆症組成物を提供すること
にある。本発明者らは、上記の目的を解決するために鋭
意研究してきた。その結果、有効成分としてビタミンK
2 を亜鉛とともに与えることにより、不荷重状態で飼育
し骨形成に障害のあるラット大腿骨骨幹端部組織に対し
て、より高い骨増強作用が発揮されることを発見し、骨
粗鬆症の予防あるいは/かつ治療のための機能性食品あ
るいは組成物を作る場合に、ビタミンK2 および亜鉛を
共に含有せしめることにより、より有効な抗骨粗鬆症組
成物を提供できることを見出した。
SUMMARY OF THE INVENTION An object of the present invention is to provide an effective anti-osteoporosis composition which can solve the above-mentioned problems. The present inventors have intensively studied to solve the above-mentioned object. As a result, vitamin K as an active ingredient
By adding 2 together with zinc, it was discovered that a higher bone augmenting effect was exerted on the metaphyseal tissue of the rat femur, which was raised under no load and had a disorder in bone formation, to prevent osteoporosis or / In addition, it has been found that a more effective anti-osteoporosis composition can be provided by incorporating vitamin K 2 and zinc together when preparing a functional food or composition for treatment.

【0009】すなわち、本発明は、ビタミンK2 と亜鉛
を共に強化した抗骨粗鬆症組成物である。ビタミンK2
と亜鉛が骨組織に対してどの様な機構で作用するのかは
定かではないが、おそらく、亜鉛の骨形成促進作用とビ
タミンK2 の破骨細胞抑制作用が協調して働くと考えら
れる。
Accordingly, the present invention is an anti-osteoporotic composition with enhanced both vitamin K 2 and zinc. Vitamin K 2
Zinc that there is but the one is not clear to act in any such mechanism for the bone tissue, probably, osteoclast inhibitory effect of bone formation promoting action and vitamin K 2 of zinc is thought to work in concert.

【0010】[0010]

【発明の実施の形態】本発明に利用されるビタミンK2
は、合成品、天然品いずれも使用できるが、食品として
用いる場合、天然由来のものが望ましく、さらに、食経
験の長い納豆あるいは枯草菌由来のビタミンK2 が望ま
しい。したがって、食品のビタミンK 2 として知られて
いるメナキノン(MK)−1〜14のいずれも使用でき
る。また、ビタミンK2 の製法は特に制限されず、ビタ
ミンK2 含量の高い納豆菌を発酵した培養液の乾燥物、
あるいは納豆菌をそのままビタミンK2 源として利用す
ることもできる。
DETAILED DESCRIPTION OF THE INVENTION Vitamin K used in the present inventionTwo 
Can be used for both synthetic and natural products.
When used, those of natural origin are desirable, and
Vitamin K from natto or Bacillus subtilisTwo Is desirable
New Therefore, vitamin K in food Two Known as
Menaquinone (MK) -1 to 14 can be used
You. Also, vitamin KTwo There is no particular limitation on the manufacturing method of
Min KTwo Dried product of fermented natto bacteria with high content,
Or natto bacteria as it is vitamin KTwo Use as a source
You can also.

【0011】本発明品に利用される亜鉛の由来は特に限
定されず、硫酸亜鉛、塩化亜鉛などの無機亜鉛やグルコ
ン酸亜鉛などの他、海水などから製造される天然塩や亜
鉛結合タンパク質やペプチド類など食品中の亜鉛濃度を
高めた製剤、さらには高濃度の亜鉛を含む食品、例えば
乾燥酵母、スッポン粉末、乾燥レバー、牛骨粉、蛎など
をそのまま亜鉛源として利用してもよい。
The origin of zinc used in the product of the present invention is not particularly limited. In addition to inorganic zinc such as zinc sulfate and zinc chloride, zinc gluconate and the like, natural salts produced from seawater and the like, zinc-binding proteins and peptides Preparations with an increased zinc concentration in foods, such as foods, and foods containing a high concentration of zinc, for example, dried yeast, turmeric powder, dried liver, beef bone meal, oysters, etc. may be used as a zinc source as they are.

【0012】本発明によって作られた組成物を摂取する
場合、症状、年齢などにより摂取量は異なるが、特に限
定されない。しかしながら、ビタミンK2 については摂
取量が45mgをこえると副作用が現れることがあるた
め、好ましくは、通常成人1日あたり0.05mg以上
で45mgより少ない範囲内で、さらに望ましくは、
0.1mg以上、10mg以下になるように製品(組成
物)を設計することが望ましい。亜鉛についても、摂取
量は限定されないが、望ましくは通常、成人、1日あた
り0.1mg以上、10mg以下になるように利用され
ることが推奨される。
When ingesting the composition prepared according to the present invention, the amount of intake varies depending on symptoms, age, etc., but is not particularly limited. However, since the vitamin K 2 have you intake side effect appears exceeds 45mg, preferably, in the range of less than 45mg in an adult per day 0.05mg above, more desirably,
It is desirable to design the product (composition) so as to be 0.1 mg or more and 10 mg or less. The intake amount of zinc is not limited, but it is generally recommended that the adult be used in an amount of 0.1 mg or more and 10 mg or less per day for an adult.

【0013】本発明による組成物は、有効成分としてビ
タミンK2 と亜鉛が共に含まれていることが重要であっ
て、カルシウム、マグネシウム、鉄、マンガン,銅など
のミネラルや、ビタミンD、ビタミンE、ユビキノンな
どのビタミン類、さらにイソフラボノイド類や、フラボ
ノイド類、カゼインカルシウムホスホネートなどのペプ
チド類、その他、タンパク質や脂質など通常の食品成分
や食品添加物が含まれていてもなんら構わない。このほ
か、製剤にあたつては製薬上許容される担体、助剤等を
用いて、粉剤、粒剤、錠剤、散剤等とすることができ
る。
It is important that the composition according to the present invention contains both vitamin K 2 and zinc as active ingredients, and minerals such as calcium, magnesium, iron, manganese and copper, vitamin D and vitamin E And vitamins such as ubiquinone, isoflavonoids, flavonoids, peptides such as casein calcium phosphonate, and other normal food ingredients and food additives such as proteins and lipids. In addition, powders, granules, tablets, powders and the like can be prepared using pharmaceutically acceptable carriers, auxiliaries and the like.

【0014】ビタミンK2 も亜鉛も食品中に極く微量含
まれていることがあるが、本発明における抗骨粗鬆症剤
においては、そのような天然に含有される極少量ではな
く、固形分1Kg中のビタミンK2 の含有量が30mg
以上(好ましくは40mg以上、更に好ましくは50m
g以上)、かつ亜鉛の含有量が30mg以上(好ましく
は40mg以上、更に好ましくは50mg以上)である
ことが望ましい。すなわち、これ以下の濃度では、顕著
な効果が発現しにくいという傾向がある。次に、本発明
を具体的に説明するため、以下に実施例を掲げるが、本
発明はこれらによって限定されるものではない。なお、
以下のビタミンK2 濃度は、高速液体クロマトグラフィ
ー法で測定し、亜鉛濃度は原子吸光法で測定した。
Although vitamin K 2 and zinc may be contained in very small amounts in foods, the anti-osteoporosis agent of the present invention does not contain such a small amount contained in nature but contains 1 kg of solid content. 30mg is the content of vitamin K 2
(Preferably 40 mg or more, more preferably 50 m
g or more) and the zinc content is preferably 30 mg or more (preferably 40 mg or more, more preferably 50 mg or more). That is, at a concentration lower than this, there is a tendency that a remarkable effect is hard to be exhibited. Next, in order to specifically explain the present invention, examples will be given below, but the present invention is not limited by these. In addition,
The following vitamin K 2 concentrations were measured by high performance liquid chromatography, and the zinc concentration was measured by atomic absorption.

【0015】[0015]

【実施例】【Example】

実施例1 粉末素材 [処方] 原料 配合量 1)納豆抽出油(ビタミンK2 濃度:500ppm ) 200g 2)乾燥酵母粉末(亜鉛濃度:150ppm ) 280g 3)トウモロコシデンプン 500g 4)抽出トコフェロール 20g 上記原料を高速ミキサーにて混合して均一な粉末が得ら
れた。この粉末は様々な食品に混合可能である。
Example 1 Powder Material [Formulation] material amount 1) natto extract oil (vitamin K 2 concentration: 500 ppm) 200 g 2) dry yeast powder (zinc concentration: 150 ppm) 280 g 3) Corn starch 500 g 4) extracted tocopherol 20g above raw materials The powder was mixed with a high-speed mixer to obtain a uniform powder. This powder can be mixed with various foods.

【0016】実施例2 飲料 牛乳1リットルに対して、0.1gのビタミンK2 (メ
ナキノン−4)、10mgの硫酸亜鉛、ココアパウダー
0.5g、砂糖30g、ショ糖脂肪酸エステル0.5g
を加えて激しく攪拌してココア味の乳飲料が得られた。
得られた飲料は、味が良く飲みやすいため、日常継続し
て飲食できる。
Example 2 Beverage For 1 liter of milk, 0.1 g of vitamin K 2 (menaquinone-4), 10 mg of zinc sulfate, 0.5 g of cocoa powder, 30 g of sugar, 0.5 g of sucrose fatty acid ester
And vigorously stirred to obtain a cocoa-flavored milk drink.
The obtained beverage has good taste and is easy to drink, so that it can be continuously eaten and consumed daily.

【0017】実施例3 錠剤 精製ビタミンK2 (メナキノン−7、濃度98%)20
gを大豆油80gに50℃で加熱しながら、溶解した
後、デキストリン粉末(松谷化学工業製パインフロー)
400gに吸着させて粉末化させてビタミンK2 粉末
(A)を作成した。 [処方] 原料 配合量 ビタミンK2 粉末(A) 50mg 食用牛骨粉 100mg 乳糖 150mg パラチノース 30mg グルコン酸亜鉛 3mg 還元麦芽糖 10mg トウモロコシデンプン 10mg セルロース粉末 10mg ビタミンD3 20IU(国際単位) 以上の配合比率で、各原料を混合し打錠して錠剤を得
た。得られた錠剤は、味がよく、携帯性に優れており、
容易に持ち運んで摂取することが可能である。
Example 3 Tablets Purified vitamin K 2 (menaquinone-7, concentration 98%) 20
g was dissolved in 80 g of soybean oil while heating at 50 ° C., and then dextrin powder (Pine Flow, manufactured by Matsutani Chemical Industry)
Vitamin K 2 powder (A) was prepared by adsorbing on 400 g and powdering. [Formulation] In the raw material mixing amount of vitamin K 2 powder (A) 50 mg edible bovine bone powder 100mg Lactose 150mg palatinose 30mg zinc gluconate 3mg reduced maltose 10mg Corn starch 10mg cellulose powder 10mg vitamin D3 20 IU (International Units) above blending ratio, the raw materials Was mixed and tableted to give tablets. The resulting tablets have good taste and excellent portability,
It is easy to carry and consume.

【0018】[0018]

【発明の性能試験】[Performance test of the present invention]

試験例1 骨粗鬆症改善効果試験 [実験方法の説明]図1に示した様に、ウイスター系ラ
ット(4週齢)1の体をワイヤー2,2で固定し後肢に
体重をかけずに、4日間飼育した。この様に後肢不荷重
状態で飼育したラット大腿骨の骨形成は障害され、骨粗
鬆症のモデルの一つとして研究されている。こうして得
られたラット大腿骨骨幹端部(海綿骨)を小片に切り出
して、培地の入った35−mm培養皿に移し、ビタミン
2 と亜鉛の骨粗鬆症改善効果試験に使用した。
Test Example 1 Osteoporosis ameliorating effect test [Explanation of Experimental Method] As shown in FIG. 1, the body of a Wistar rat (4 weeks old) 1 was fixed with wires 2 and 2 and no weight was applied to the hind limbs for 4 days. Bred. In this way, bone formation in rat femurs reared in a hindlimb unloaded state is impaired and studied as one of the models of osteoporosis. Thus obtained rat femoral metaphysis part (cancellous bone) cut into small pieces and transferred to 35-mm culture dishes in medium was used to osteoporosis improving effect test of vitamin K 2 and zinc.

【0019】培地は、0.25%の牛血清アルブミンと
抗生物質(100単位ペニシリンと100μgストレプ
トマイシン/ml培地)を含む2.0mlのダルベッコ
の改変イーグル培地(グルコース濃度4.5g/dl)
を使用した。組織培養は、CO2 インキュベーターを用
いて、37℃、水飽和雰囲気下で5%CO2 および95
%空気の条件で48時間行った。ビタミンK2 は納豆に
含まれるメナキノン−7(MK−7)を純度99.8%
まで精製し、エタノールに溶解して1mMに濃度調整し
たものを使用した。
The medium was 2.0 ml of Dulbecco's modified Eagle's medium (glucose concentration 4.5 g / dl) containing 0.25% bovine serum albumin and antibiotics (100 units penicillin and 100 μg streptomycin / ml medium).
It was used. Tissue culture was performed using a CO 2 incubator at 37 ° C., 5% CO 2 and 95% in a water-saturated atmosphere.
% Air for 48 hours. Vitamin K 2 is 99.8% pure menaquinone-7 (MK-7) contained in natto
Purified, dissolved in ethanol, and adjusted to a concentration of 1 mM.

【0020】培地に、納豆由来ビタミンK2 (MK−
7)を10-5M(最終濃度)加えたもの、10-5
ZnSO4 を加えたもの、10-5M ビタミンK2
10 -5M ZnSO4 を併用したもの、対照(コント
ロール)として溶媒だけ加えたものの4条件を試験し、
培養後の骨組織中のカルシウム量を比較した。カルシウ
ム量は、骨組織乾燥重量あたりのカルシウム量で表し
た。乾燥重量は、骨組織を110℃で24時間乾燥し、
測定した。カルシウム量は、乾燥した骨組織を120℃
にて48時間、3ml硝酸溶液により分解し、原子吸光
計で測定した。
In the medium, natto-derived vitamin KTwo (MK-
7) to 10-FiveM (final concentration) added, 10-FiveM
ZnSOFour Plus 10-FiveM vitamin KTwo When
10 -FiveM ZnSOFour And control (control
Roll) was tested for 4 conditions with only solvent added,
The amount of calcium in the bone tissue after the culture was compared. Calciu
The amount of calcium is expressed as calcium per dry weight of bone tissue.
Was. Dry weight is to dry the bone tissue at 110 ° C. for 24 hours,
It was measured. The amount of calcium was 120 ° C for dried bone tissue.
Decomposed with 3 ml nitric acid solution for 48 hours
It was measured with a meter.

【0021】[実験結果の説明]4日間後肢不荷重状態
(骨形成が障害される)で飼育したラット(5匹)の大
腿骨骨幹端部組織を用いて、培養液に天然ビタミンK2
(メナキノン−7)、亜鉛を単独あるいは混合して添加
し、48時間後のカルシウム量を測定した結果を表1に
示す。
[Explanation of Experimental Results] Using the metaphyseal tissue of the femur of rats (5 rats) bred under unloaded hind limbs (bone formation is impaired) for 4 days, natural vitamin K 2 was added to the culture medium.
Table 1 shows the results obtained by adding (menaquinone-7) and zinc singly or as a mixture, and measuring the amount of calcium after 48 hours.

【0022】 * p<0.005 、 ** p<0.01[0022] * p <0.005, ** p <0.01

【0023】表1に示すように、ビタミンK2 を単独添
加しても、骨組織中のカルシウム量はコントロールと比
較して有意に増加しなかったが、一方で、ZnSO4
加でカルシウム量は増加した。このように、ビタミンK
2 単独では効果が現われないにもかかわらずZnSO4
と併用した場合では、ZnSO4 単独使用時よりも高い
骨組織中カルシウム量の増加効果が認められた。ビタミ
ンK2 単独で充分な骨作用を示すのに必要な1日成人投
与量45mgでは副作用が現れることがあるため、骨粗
鬆症予防のためにはこれより少ない量のビタミンK2
摂取が望まれるが、本発明によれば、ビタミンK2 の単
独投与では骨粗鬆症の改善、予防に効果が現れないよう
な投与量であっても、亜鉛と共に摂取することにより、
ビタミンK2 と亜鉛が相互作用し、より高い骨作用が促
進されることが明白である。本発明組成物は、副作用が
ない抗骨粗鬆症効果ゆえ、若い時期から日常的に予防目
的で摂取することができるため、個人の老後の生活の質
を守るだけでなく、高齢化社会の医療費削減への貢献が
期待できる。同時に、本発明により提供できる組成物
は、ビタミンK2 と亜鉛を同時に摂取でき、栄養成分の
強化も行うことができる。
As shown in Table 1, the addition of vitamin K 2 alone did not significantly increase the calcium content in bone tissue as compared with the control, whereas the addition of ZnSO 4 reduced the calcium content. Increased. Thus, vitamin K
Even though the effect does not appear in the 2 alone ZnSO 4
When used in combination with ZnSO 4 , the effect of increasing the amount of calcium in bone tissue was higher than when ZnSO 4 was used alone. Vitamin K 2 for alone may appear one day adult dose 45mg side effects in required to provide a sufficient bone effect, but lesser amount of intake of vitamin K 2 is desired for osteoporosis prevention According to the present invention, improvement of osteoporosis alone administration of vitamin K 2, even doses as effect does not appear to prevent, by ingesting with zinc,
Vitamin K 2 and zinc interact, it is apparent that a higher bone effect is promoted. Since the composition of the present invention can be taken daily for preventive purposes from a young age due to its anti-osteoporotic effect without side effects, it not only protects the quality of life of individuals after retirement but also reduces medical costs in an aging society. Can be expected to contribute. At the same time, compositions which can be provided by the present invention, vitamin K 2 and zinc can ingest simultaneously, it can be carried out also strengthening nutrients.

【0024】試験例2 安全性試験 実施例1で調製した粉末製剤および実施例3で示した錠
剤の急性毒性試験を以下の方法で行った。 [試験方法]4週齢のddy系マウスのオスを1群10
匹使用した。被検物質の投与が個体体重に対して10g
/kgおよび5g/kgの2群を編成し、18時間絶食
した後、マーゲンゾンデを用いて強制経口投与した。マ
ウスは恒温高湿の条件で飼育し、投与日を0として各個
体の体重を測定しつつ、7日間一般症状および生死の状
態を観察した。この間水と餌は自由に与えた。
Test Example 2 Safety Test The acute toxicity test of the powder preparation prepared in Example 1 and the tablet shown in Example 3 was performed by the following method. [Test Method] Male ddy mice of 4 weeks old were grouped in groups of 10
Used. The administration of the test substance is 10 g based on the body weight of the individual.
/ Kg and 5 g / kg were grouped, fasted for 18 hours, and then administered by oral gavage using a magensonde. The mice were bred under conditions of constant temperature and high humidity, and the body weight of each individual was measured while the administration day was 0, and the general symptoms and the state of life and death were observed for 7 days. Water and food were provided ad libitum during this time.

【0025】[試験結果]粉末製剤(実施例1)ならび
に錠剤(実施例3)とも、死亡例は認められず、体重も
順調に増加した。また、外観も通常のマウスと何ら変わ
りがなかった。したがって、両被検物質とも、LD50
10g/kgより大きく、極めて安全な組成物であるこ
とがわかった。また、ビタミンK2 、亜鉛とも食品中に
広く含まれているものであることから、慢性毒性に関し
ても極めて安全性の高い素材であると判断される。
[Test Results] In both the powder preparation (Example 1) and the tablet (Example 3), no fatal cases were observed, and the body weight increased steadily. The appearance was not different from a normal mouse. Therefore, both test substances had an LD 50 of more than 10 g / kg, which proved to be an extremely safe composition. In addition, since vitamin K 2 and zinc are widely contained in foods, it is determined that they are extremely safe materials with respect to chronic toxicity.

【図面の簡単な説明】[Brief description of the drawings]

【図1】試験ラットの飼育状態を示す斜視図である。FIG. 1 is a perspective view showing a rearing state of a test rat.

【符号の説明】[Explanation of symbols]

1 ラット 2 ワイヤー 1 rat 2 wires

Claims (5)

【特許請求の範囲】[Claims] 【請求項1】 ビタミンK2 と亜鉛を共に強化した、抗
骨粗鬆症組成物。
1. An anti-osteoporotic composition in which both vitamin K 2 and zinc are fortified.
【請求項2】 ビタミンK2 が天然物より抽出した天然
ビタミンK2 である請求項第1項記載の組成物。
2. A composition as in claim 1 wherein the natural vitamin K 2 vitamin K 2 is extracted from natural products.
【請求項3】 ビタミンK2 が枯草菌あるいは納豆菌由
来である請求項第1項または第2項記載の組成物。
3. The composition according to claim 1, wherein the vitamin K 2 is derived from Bacillus subtilis or Bacillus natto.
【請求項4】 亜鉛が食品由来である請求項第1項ない
し第3項のいずれか1項に記載の組成物。
4. The composition according to claim 1, wherein the zinc is derived from food.
【請求項5】 固形分1Kg中のビタミンK2 の含有量
が30mg以上、かつ亜鉛の含有量が30mg以上であ
る請求項第1項ないし第4項のいずれか1項に記載の組
成物。
5. The composition according to claim 1, wherein the content of vitamin K 2 in 1 kg of solid content is 30 mg or more and the content of zinc is 30 mg or more.
JP19312496A 1996-07-23 1996-07-23 Anti-osteoporosis composition Expired - Lifetime JP3459932B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP19312496A JP3459932B2 (en) 1996-07-23 1996-07-23 Anti-osteoporosis composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP19312496A JP3459932B2 (en) 1996-07-23 1996-07-23 Anti-osteoporosis composition

Publications (2)

Publication Number Publication Date
JPH1036256A true JPH1036256A (en) 1998-02-10
JP3459932B2 JP3459932B2 (en) 2003-10-27

Family

ID=16302669

Family Applications (1)

Application Number Title Priority Date Filing Date
JP19312496A Expired - Lifetime JP3459932B2 (en) 1996-07-23 1996-07-23 Anti-osteoporosis composition

Country Status (1)

Country Link
JP (1) JP3459932B2 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2370503A (en) * 2000-12-27 2002-07-03 Novartis Nutrition Ag Compositions comprising vitamin K
WO2004037236A1 (en) * 2002-10-25 2004-05-06 KEMIN FOODS, L. C. d/b/a KEMIN HEALTH, L. C. OSTEOGENESIS PROMOTER CONTAINING β-CRYPTOXANTHIN AS THE ACTIVE INGREDIENT
WO2005030190A1 (en) * 2003-09-26 2005-04-07 Natural Asa Natural menaquinone 7 compositions
WO2011031601A3 (en) * 2009-09-14 2011-06-03 Nestec S.A. Nutritional compositions including exogenous vitamin k2
JP5967936B2 (en) * 2009-03-13 2016-08-10 株式会社明治 Composition for reducing fracture risk and / or preventing fracture
AU2014304510B2 (en) * 2013-08-08 2017-03-16 Kappa Bioscience As Compositions comprising vitamin K derivatives and salts
CN106615099A (en) * 2016-10-12 2017-05-10 西宝生物科技(上海)股份有限公司 Yoghourt including MK-7 and active vitamin D3 and preparation method of yoghourt
CN112795608A (en) * 2021-02-10 2021-05-14 河北省科学院生物研究所 Method for preparing polypeptide-enriched chelated calcium products based on active microbial strains
JP2021112138A (en) * 2020-01-17 2021-08-05 理研ビタミン株式会社 Flavor preservative

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ589810A (en) 2008-06-03 2012-11-30 John Ray Biffin A method for increasing bone density and/or reducing any osteochondral defects in an equne or avian and a composition including vitamin k
FR3034665B1 (en) * 2015-04-10 2018-09-21 Sp2L COMPOSITION COMPRISING VITAMIN K2, ZINC AND VITAMIN D

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424331A (en) * 1994-06-10 1995-06-13 Bio-Virus Research Incorporated Pharmaceutical compositions and dietary soybean food products for the prevention of osteoporosis
JPH089916A (en) * 1994-07-05 1996-01-16 Asahimatsu Shokuhin Kk Method for producing natto with high vitamin K content
JPH0819378A (en) * 1994-07-07 1996-01-23 Asahimatsu Shokuhin Kk Manufacturing method of food material with high vitamin K content
JPH0873396A (en) * 1994-07-07 1996-03-19 Honen Corp Lipid having high natural menaquinone-7 content

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424331A (en) * 1994-06-10 1995-06-13 Bio-Virus Research Incorporated Pharmaceutical compositions and dietary soybean food products for the prevention of osteoporosis
JPH089916A (en) * 1994-07-05 1996-01-16 Asahimatsu Shokuhin Kk Method for producing natto with high vitamin K content
JPH0819378A (en) * 1994-07-07 1996-01-23 Asahimatsu Shokuhin Kk Manufacturing method of food material with high vitamin K content
JPH0873396A (en) * 1994-07-07 1996-03-19 Honen Corp Lipid having high natural menaquinone-7 content

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2370503A (en) * 2000-12-27 2002-07-03 Novartis Nutrition Ag Compositions comprising vitamin K
WO2004037236A1 (en) * 2002-10-25 2004-05-06 KEMIN FOODS, L. C. d/b/a KEMIN HEALTH, L. C. OSTEOGENESIS PROMOTER CONTAINING β-CRYPTOXANTHIN AS THE ACTIVE INGREDIENT
US8148431B2 (en) 2002-10-25 2012-04-03 Kemin Health, L.C. Osteogenesis promoter containing β-cryptoxanthin as the active ingredient
WO2005030190A1 (en) * 2003-09-26 2005-04-07 Natural Asa Natural menaquinone 7 compositions
JP5967936B2 (en) * 2009-03-13 2016-08-10 株式会社明治 Composition for reducing fracture risk and / or preventing fracture
WO2011031601A3 (en) * 2009-09-14 2011-06-03 Nestec S.A. Nutritional compositions including exogenous vitamin k2
JP2013504571A (en) * 2009-09-14 2013-02-07 ネステク ソシエテ アノニム Nutritional composition containing exogenous vitamin K2
AU2014304510B2 (en) * 2013-08-08 2017-03-16 Kappa Bioscience As Compositions comprising vitamin K derivatives and salts
CN106615099A (en) * 2016-10-12 2017-05-10 西宝生物科技(上海)股份有限公司 Yoghourt including MK-7 and active vitamin D3 and preparation method of yoghourt
JP2021112138A (en) * 2020-01-17 2021-08-05 理研ビタミン株式会社 Flavor preservative
CN112795608A (en) * 2021-02-10 2021-05-14 河北省科学院生物研究所 Method for preparing polypeptide-enriched chelated calcium products based on active microbial strains
CN112795608B (en) * 2021-02-10 2022-07-01 河北省科学院生物研究所 Method for preparing polypeptide-enriched chelated calcium product based on active microbial strains

Also Published As

Publication number Publication date
JP3459932B2 (en) 2003-10-27

Similar Documents

Publication Publication Date Title
JPH082268B2 (en) Dietary products containing methylsulfonylmethane and their use
AU718218B2 (en) Dietary supplements
EP1528864B1 (en) Calcium absorption enhancer
JP2024122087A (en) Free amino acid absorption enhancer and method for enhancing absorption of free amino acids
JPH07252156A (en) Medicine for prevention and therapy of osteoporosis
JP3459932B2 (en) Anti-osteoporosis composition
CN101166429A (en) Alimentation composition
KR20070113460A (en) Healthy food composition for weight control
WO2009082883A1 (en) Antiobesity composition
JP2002234844A (en) Bone density improver and utilization thereof
JPH07277991A (en) Mineral absorption-stimulating agent
US20040052918A1 (en) High energy complete food or nutritional supplement, method for preparing same and uses thereof
EP1242067B1 (en) Calcium formate as a dietary supplement
EP2196099B1 (en) Immuno-nutritional composition
TW201410238A (en) COMPOSITION COMPRISING SESAMIN COMPOUND, gamma-ORIZANOL AND RICE GERM OIL
JPH0797323A (en) Iron absorption promoter
CA2408611A1 (en) Kits and methods for optimizing the efficacy of chondroprotective compositions
JP4914594B2 (en) Food composition for improving joint pain
JP3250071B2 (en) Anti-osteoporosis composition
JP3005794B2 (en) Bone mass enhancing composition exhibiting anti-osteoporosis effect
TWI530256B (en) Method for producing anti-mental fatigue agent utilizing ferro-bound lactoferrin
JP2000139411A (en) Food and drink including isoflavone together with peptide
EP1599198B1 (en) Potassium taurate bicarbonate and ascorbate complexes
JP2021069308A (en) Orally-taken composition
CN112514996B (en) Combination or composition, dairy product and use

Legal Events

Date Code Title Description
S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090815

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090815

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090815

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100815

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100815

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110815

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110815

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120815

Year of fee payment: 9

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120815

Year of fee payment: 9

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120815

Year of fee payment: 9

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130815

Year of fee payment: 10

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term